Advantage Alpha Capital Partners LP Sells 21,053 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Advantage Alpha Capital Partners LP decreased its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 45.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 25,098 shares of the biopharmaceutical company’s stock after selling 21,053 shares during the quarter. Advantage Alpha Capital Partners LP’s holdings in Dynavax Technologies were worth $321,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Smartleaf Asset Management LLC boosted its holdings in Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 2,034 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 1,457 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Dynavax Technologies in the 4th quarter worth about $71,000. Nisa Investment Advisors LLC grew its position in Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 1,076 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Dynavax Technologies in the 3rd quarter valued at about $89,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Trading Up 0.1 %

NASDAQ:DVAX opened at $13.84 on Tuesday. The firm’s 50 day moving average is $13.24 and its 200 day moving average is $12.43. Dynavax Technologies Co. has a 12 month low of $9.74 and a 12 month high of $14.63. The stock has a market capitalization of $1.72 billion, a PE ratio of 76.89 and a beta of 1.23. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.05. The company had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. Sell-side analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on DVAX shares. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st. HC Wainwright restated a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. Finally, The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and cut their price target for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.